secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001558370-24-000740
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus amends loan with Pharmakon; to prepay $175M, reduce interest ~70%
-------------------------------------------------------------------------

- After closing ophthalmology divestiture to Sandoz, Coherus will prepay $175M of $250M loan principal, leaving $75M residual.
- Revenue covenant reduced to $125M under amended loan agreement with Pharmakon Advisors.
- Projected annual interest expense on term loan reduced by approximately 70%.
- Prepayment expected in Q2 2024; strengthens balance sheet for oncology growth.
- Amendment also provides consent and releases collateral tied to Sandoz transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024000740/0001558370-24-000740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024000740/chrs-20240205x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-000740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer